Cardiogenic Pulmonary Edema in Emergency Medicine.
Christian ZanzaFrancesco SagliettiManfredi TesauroYaroslava LonghitanoGabriele SavioliMario Giosuè BalzanelliTatsiana RomenskayaLuigi CofoneIvano PindinelloGiulia RaccaFabrizio RaccaPublished in: Advances in respiratory medicine (2023)
Cardiogenic pulmonary edema (CPE) is characterized by the development of acute respiratory failure associated with the accumulation of fluid in the lung's alveolar spaces due to an elevated cardiac filling pressure. All cardiac diseases, characterized by an increasing pressure in the left side of the heart, can cause CPE. High capillary pressure for an extended period can also cause barrier disruption, which implies increased permeability and fluid transfer into the alveoli, leading to edema and atelectasis. The breakdown of the alveolar-epithelial barrier is a consequence of multiple factors that include dysregulated inflammation, intense leukocyte infiltration, activation of procoagulant processes, cell death, and mechanical stretch. Reactive oxygen and nitrogen species (RONS) can modify or damage ion channels, such as epithelial sodium channels, which alters fluid balance. Some studies claim that these patients may have higher levels of surfactant protein B in the bloodstream. The correct approach to patients with CPE should include a detailed medical history and a physical examination to evaluate signs and symptoms of CPE as well as potential causes. Second-level diagnostic tests, such as pulmonary ultrasound, natriuretic peptide level, chest radiograph, and echocardiogram, should occur in the meantime. The identification of the specific CPE phenotype is essential to set the most appropriate therapy for these patients. Non-invasive ventilation (NIV) should be considered early in the treatment of this disease. Diuretics and vasodilators are used for pulmonary congestion. Hypoperfusion requires treatment with inotropes and occasionally vasopressors. Patients with persistent symptoms and diuretic resistance might benefit from additional approaches (i.e., beta-agonists and pentoxifylline). This paper reviews the pathophysiology, clinical presentation, and management of CPE.
Keyphrases
- respiratory failure
- pulmonary hypertension
- end stage renal disease
- cell death
- newly diagnosed
- ejection fraction
- chronic kidney disease
- healthcare
- magnetic resonance imaging
- left ventricular
- emergency medicine
- mental health
- combination therapy
- cell proliferation
- computed tomography
- patient reported outcomes
- escherichia coli
- smoking cessation
- binding protein
- endothelial cells
- pi k akt
- human health
- cell cycle arrest